Pfizer to acquire King for $3.56bn, gains pain portfolio
Pfizer Inc. has agreed to pay $14.25 (a 42% premium) for each outstanding share of specialty pharmaco King Pharmaceuticals Inc., valuing the acquisition at $3.56bn.
- Medical Devices
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.